Abstract Purpose of Review It is clear from epidemiological studies that patients at high and
very-high risk of atherosclerotic cardiovascular diseases (ASCVD) risk do not reach lipid …

Novel imaging techniques and biomarkers have emerged as surrogate markers of carotid
plaque vulnerability. In parallel, statin administration in patients with established carotid …

Background Multiple pleiotropic effects of statins include antithrombotic properties with
formation of looser fibrin networks more susceptible to lysis. Recently, rosuvastatin 20 mg/d …

In this context, we report the first electrochemical sensing platform for the simultaneous
quantitation of two antihyperlipidemic drugs, namely, atorvastatin (ATR) and ezetimibe …

The modern history of cholesterol-lowering drugs started in 1972 when Dr. Akira Endo
identified an active compound (compactin) that inhibited cholesterol biosynthesis from the …

Calcific Aortic Valve Disease (CAVD) is a fibrocalcific disease. Lipoproteins and oxidized
phospholipids play a substantial role in CAVD; the level of Lp (a) has been shown to …

Background: The triglyceride-glucose index (TyG index) is a novel metabolic marker initially
used as an indicator of insulin resistance. Recently, its use as a cardiovascular risk factor …

Calcific aortic stenosis (CAS) is the most common cause of acquired valvular heart disease
in adults with no available pharmacological treatment to inhibit the disease progression to …

Background Aortic stenosis (AS) prevalence is estimated to reach 4.5 million cases
worldwide by the year 2030. AS is a progressive disease without a pharmacological …

Objective Studies on the effect of statins on platelets in patients with coronary artery disease
(CAD) yielded inconsistent results. We sought to investigate whether high-dose statin …